ISO: AI 评分 43/100 — AI 分析 (4月 2026)

IsoPlexis Corporation is a life sciences company focused on single-cell proteomics, offering instruments, consumables, and software for developing curative medicines and personalized therapeutics. The company operates globally, providing tools for analyzing protein function at the individual cellular level.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

IsoPlexis Corporation provides single-cell proteomics solutions, including instruments and software, for the development of curative medicines and personalized therapeutics. Operating globally, the company's platform enables researchers to analyze protein function at a cellular level, positioning it within the medical devices sector focused on advanced biological research tools.

ISO是做什么的？

IsoPlexis Corporation, established in 2013 and headquartered in Branford, Connecticut, is a life sciences company specializing in single-cell proteomics. The company develops and commercializes solutions that enable researchers to gain a comprehensive understanding of cellular function at the individual cell level, which is crucial for developing curative medicines and personalized therapeutics. IsoPlexis operates across the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China, Taiwan, Singapore, Japan, Australia, and Korea. IsoPlexis's core offering is its single-cell proteomics platform, which includes instruments like IsoLight and IsoSpark, chip consumables such as IsoCode and CodePlex chips, and IsoSpeak software. The IsoLight and IsoSpark instruments are designed for high-throughput single-cell analysis. IsoCode chips provide multiplexed solutions for single-cell functional proteomics, while CodePlex chips cater to ultra-low volume bulk samples. IsoSpeak software automates data analysis, providing visualizations of single-cell and bulk proteomes. The company also offers research support, services, and post-warranty services. IsoPlexis's technology addresses the growing need for precise and personalized medicine by enabling researchers to identify and characterize functionally distinct cell populations. This capability is particularly valuable in fields such as oncology, immunology, and infectious diseases, where understanding cellular heterogeneity is essential for developing effective therapies.

ISO的投资论点是什么？

IsoPlexis Corporation presents a unique investment opportunity within the life sciences sector, driven by its innovative single-cell proteomics platform. The increasing demand for personalized medicine and targeted therapies is a key value driver, as IsoPlexis's technology enables researchers to gain deeper insights into cellular function. A potential growth catalyst is the expansion of the company's product portfolio and geographic reach, particularly in emerging markets. However, the company's negative profit margin of -689.1% and gross margin of -5.5% represent significant risk factors. Investors should closely monitor the company's ability to improve its financial performance and achieve profitability. The market capitalization of $0.03 billion reflects the early stage and high-risk nature of this investment.

ISO在哪个行业运营？

IsoPlexis Corporation operates within the medical devices industry, a segment of the broader healthcare sector characterized by rapid innovation and technological advancements. The industry is driven by the increasing demand for personalized medicine, targeted therapies, and advanced diagnostic tools. The single-cell analysis market is experiencing substantial growth, fueled by advancements in proteomics and genomics. IsoPlexis competes with companies offering similar technologies, such as ALLK, ANGN, ANPC, ELUT, and HEXO, as well as larger players in the life sciences industry. The company's success depends on its ability to differentiate its platform, expand its customer base, and navigate the complex regulatory landscape.

Medical - Devices

Healthcare

ISO有哪些增长机遇？

Expansion into Emerging Markets: IsoPlexis has the opportunity to expand its presence in emerging markets, particularly in Asia-Pacific, where the demand for advanced healthcare technologies is growing rapidly. These regions represent a significant market opportunity, driven by increasing healthcare spending and a growing focus on personalized medicine. Successfully penetrating these markets could significantly increase IsoPlexis's revenue and market share. The timeline for this expansion is ongoing, with potential for significant growth within the next 3-5 years.
Development of New Applications: IsoPlexis can leverage its single-cell proteomics platform to develop new applications in areas such as drug discovery, biomarker identification, and disease diagnostics. By expanding its product portfolio to address these emerging needs, IsoPlexis can attract new customers and increase its revenue streams. The market for these applications is substantial, with significant growth potential in the coming years. The timeline for developing these new applications is estimated to be 2-3 years.
Strategic Partnerships and Collaborations: IsoPlexis can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other healthcare providers to accelerate the adoption of its technology and expand its market reach. These partnerships can provide access to new markets, funding, and expertise, enabling IsoPlexis to grow more rapidly. The timeline for establishing these partnerships is ongoing, with potential for significant impact within the next 1-2 years.
Enhancement of Software and Data Analytics Capabilities: IsoPlexis can enhance its IsoSpeak software and data analytics capabilities to provide customers with more comprehensive and actionable insights. By developing advanced algorithms and machine learning tools, IsoPlexis can enable researchers to analyze complex datasets more efficiently and identify novel therapeutic targets. The market for data analytics in healthcare is growing rapidly, driven by the increasing volume of data generated by genomic and proteomic technologies. The timeline for enhancing these capabilities is estimated to be 1-2 years.
Focus on Personalized Medicine: IsoPlexis can capitalize on the growing trend towards personalized medicine by developing solutions that enable researchers to tailor therapies to individual patients based on their unique cellular profiles. By providing tools for identifying and characterizing functionally distinct cell populations, IsoPlexis can help researchers develop more effective and targeted treatments. The market for personalized medicine is expected to grow significantly in the coming years, driven by advancements in genomics, proteomics, and other omics technologies. The timeline for this focus is ongoing, with potential for significant impact within the next 3-5 years.

IsoPlexis operates in the life sciences sector, providing solutions for curative medicines and personalized therapeutics.
The company's single-cell proteomics platform offers instruments, chip consumables, and software for analyzing protein function at the cellular level.
IsoPlexis has a global presence, serving customers in the United States, Europe, and Asia-Pacific regions.
The company's market capitalization is $0.03 billion, reflecting its early-stage growth potential.
IsoPlexis's negative profit margin of -689.1% indicates significant challenges in achieving profitability.

ISO提供哪些产品和服务？

Provides single-cell proteomics platform.
Offers instruments for single-cell analysis (IsoLight and IsoSpark).
Develops chip consumables for functional proteomics (IsoCode and CodePlex).
Creates software for data analysis and visualization (IsoSpeak).
Supports research and development of curative medicines.
Enables personalized therapeutics through cellular-level analysis.
Offers post-warranty services for its products.

ISO如何赚钱？

Sales of Instruments: Generates revenue from the sale of IsoLight and IsoSpark instruments.
Consumables Sales: Revenue from the sale of IsoCode and CodePlex chips.
Software Licensing: Revenue from licensing IsoSpeak software.
Service and Support: Revenue from research support, services, and post-warranty services.

Pharmaceutical companies involved in drug discovery and development.
Research institutions conducting basic and translational research.
Biotechnology companies focused on personalized medicine.
Healthcare providers offering advanced diagnostic and therapeutic services.

Proprietary Technology: IsoPlexis's single-cell proteomics platform is protected by patents and trade secrets.
High Switching Costs: Customers who have invested in IsoPlexis's platform may face high switching costs due to the need to retrain personnel and revalidate assays.
Network Effects: The value of IsoPlexis's platform increases as more researchers use it and share their data and insights.
Established Customer Base: IsoPlexis has an established customer base of pharmaceutical companies, research institutions, and biotechnology companies.

什么因素可能推动ISO股价上涨？

Upcoming: Potential partnerships with major pharmaceutical companies to integrate IsoPlexis's technology into drug development workflows.
Ongoing: Increasing adoption of single-cell proteomics in cancer research and personalized medicine.
Upcoming: Launch of new IsoCode chip configurations to expand the range of analytes that can be measured.
Ongoing: Expansion of IsoPlexis's sales and marketing efforts in key geographic markets.

ISO的主要风险是什么？

Potential: Competition from established players in the life sciences industry with greater financial resources.
Ongoing: Negative profit margin and gross margin, indicating challenges in achieving profitability.
Potential: Technological advancements by competitors that could render IsoPlexis's platform obsolete.
Ongoing: Reliance on a relatively small number of customers, increasing vulnerability to customer attrition.

ISO的核心优势是什么？

Innovative single-cell proteomics platform.
Comprehensive product portfolio including instruments, consumables, and software.
Global presence with customers in key markets.
Strong focus on personalized medicine and targeted therapies.

ISO的劣势是什么？

Negative profit margin and gross margin.
Limited financial resources compared to larger competitors.
Reliance on a relatively small number of customers.
High operating expenses.

ISO有哪些机遇？

Expansion into emerging markets.
Development of new applications for its platform.
Strategic partnerships and collaborations.
Enhancement of software and data analytics capabilities.

ISO面临哪些威胁？

Competition from larger and more established companies.
Technological advancements by competitors.
Regulatory changes and reimbursement challenges.
Economic downturns and reduced healthcare spending.

ISO的竞争对手是谁？

Allakos Inc — Focuses on antibody-based therapeutics. — (ALLK)
Angion Biomedica Corp — Develops therapeutics for fibrotic diseases. — (ANGN)
AnPac Bio-Medical Science Co Ltd — Focuses on early cancer screening and detection. — (ANPC)
Elutia Inc — Develops biomaterials for surgical applications. — (ELUT)
HEXO Corp — Cannabis company (less direct competitor, but in the broader healthcare space). — (HEXO)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Sean Mackay
Headquarters: Branford, US
Employees: 290
Founded: 2021

AI Insight

AI analysis pending for ISO

常见问题

What does IsoPlexis Corporation do?

IsoPlexis Corporation is a life sciences company that provides single-cell proteomics solutions. Its core offering is a platform that includes instruments (IsoLight and IsoSpark), chip consumables (IsoCode and CodePlex), and software (IsoSpeak) designed to analyze protein function at the individual cellular level. This technology enables researchers to gain insights into cellular heterogeneity, which is crucial for developing curative medicines and personalized therapeutics, particularly in areas like oncology, immunology, and infectious diseases. IsoPlexis serves pharmaceutical companies, research institutions, and biotechnology companies globally.

What do analysts say about ISO stock?

AI analysis is pending for ISO, so current analyst ratings and price targets are unavailable. Investors should monitor for updates on analyst coverage as it becomes available. Key valuation metrics to consider include the company's market capitalization, revenue growth rate, and profitability. Given the company's negative profit margin, investors should focus on its ability to improve its financial performance and achieve profitability. The company's growth potential is tied to the increasing adoption of single-cell proteomics in research and drug development.

What are the main risks for ISO?

IsoPlexis faces several key risks, including intense competition from larger and more established companies in the life sciences industry. Its negative profit margin and gross margin highlight the challenges in achieving profitability. Technological advancements by competitors could render IsoPlexis's platform obsolete. The company's reliance on a relatively small number of customers increases its vulnerability to customer attrition. Regulatory changes and reimbursement challenges could also impact its ability to commercialize its products and services. Economic downturns and reduced healthcare spending could further constrain its growth prospects.

How does IsoPlexis Corporation's technology impact personalized medicine?

IsoPlexis Corporation's single-cell proteomics platform plays a crucial role in advancing personalized medicine. By enabling researchers to analyze protein function at the individual cell level, IsoPlexis's technology provides insights into cellular heterogeneity and functional diversity. This information is essential for developing targeted therapies that are tailored to the unique characteristics of each patient's cells. The ability to identify and characterize functionally distinct cell populations allows for the development of more effective and personalized treatments, particularly in areas such as oncology and immunology. This capability aligns with the growing trend towards personalized medicine and the increasing demand for targeted therapies.

What is IsoPlexis Corporation's strategy for expanding its market share in the competitive medical devices industry?

IsoPlexis Corporation's strategy for expanding its market share in the competitive medical devices industry involves several key initiatives. These include expanding its geographic presence, particularly in emerging markets with high growth potential; developing new applications for its single-cell proteomics platform in areas such as drug discovery and biomarker identification; pursuing strategic partnerships and collaborations with pharmaceutical companies and research institutions; enhancing its IsoSpeak software and data analytics capabilities; and focusing on the growing trend towards personalized medicine by developing solutions that enable researchers to tailor therapies to individual patients. By executing these strategies, IsoPlexis aims to differentiate itself from competitors and increase its market share in the long term.